| |
|
|
|
|
|
|
|||
|
Blood, 1 March 2004, Vol. 103, No. 5, pp. 1909-1911. Prepublished online as a Blood First Edition Paper on November 6, 2003; DOI 10.1182/blood-2003-07-2577.
NEOPLASIA Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemiaFrom the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Pediatric Oncology, Harvard Medical School, Boston, MA; Clinical Research Institute of Montréal, Montréal, QC, Canada; and Shannon McCormack Advanced Molecular Diagnostics Laboratory, Dana-Farber Cancer Institute, Boston, MA.
Aberrant expression of transcription factor oncogenes such as HOX11, HOX11L2, TAL1/SCL, LYL1, LMO1, and LMO2 can be detected in lymphoblasts from up to 80% of patients with acute T-cell lymphoblastic leukemia (T-ALL). Transcriptional activation of these oncogenes in leukemic cells typically results from chromosomal rearrangements that place them next to highly active cis-acting transcriptional regulatory elements. However, biallelic activation of TAL1 in some T-ALL cases has been previously proposed. We have used allele-specific mRNA analysis to show that trans-acting mechanisms leading to biallelic overexpression of TAL1 are involved in 10 (42%) of 24 TAL1+ informative T-ALL cases, 2 (17%) of 12 HOX11+ informative cases, and 7 (64%) of 11 LMO2+ informative cases. We propose that aberrant expression of oncogenic transcription factors in a significant fraction of T-ALLs may result from loss of the upstream transcriptional mechanisms that normally down-regulate the expression of these oncogenes during T-cell development.
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2004 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||